Abstract
Background Heart failure (HF) with improved ejection fraction (HFimpEF) has better outcomes than HF with reduced ejection fraction (HFrEF). However, factors contributing to HFimpEF remain unclear. This study aimed to evaluate clinical and longitudinal characteristics associated with subsequent HFimpEF.
Methods This was a single-center retrospective HFrEF cohort study. Data were collected from 2014 to 2022. Patients with HFrEF were identified using ICD codes, echocardiographic data, and natriuretic peptide levels. The main endpoints were HFimpEF (defined as ejection fraction >40% at ≥3 months with ≥10% increase) and mortality. Cox proportional hazards and mixed effects models were used for analyses.
Results The study included 1307 HFrEF patients with a median follow-up of 16.3 months (IQR 8.0-30.6). The median age was 65 years; 68% were male while 57% were white. On follow-up, 39% (n=506) developed HFimpEF, while 61% (n=801) had persistent HFrEF. A multivariate Cox regression model identified sex, race comorbidities, echocardiographic, and natriuretic peptide as significant covariates of HFimpEF (p<0.05). The HFimpEF group had better survival compared to the persistent HFrEF group (p<0.001). Echocardiographic and laboratory trajectories differed between groups.
Conclusion In this HFrEF cohort, 39% transitioned to HFimpEF and approximately 50% met the definition within the first 12 months. In a HFimpEF model, sex, comorbidities, echocardiographic parameters, and natriuretic peptide were associated with subsequent HFimpEF. The model has the potential to identify patients at risk of subsequent persistent or improved HFrEF, thus informing the design and implementation of targeted quality-of-care improvement interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by NIH HeartShare (NIH U01HL160274) and the American Heart Association (AHA) (grant 23SFRNPCS1064232, 23SFRNPCS1060482, and 23SFRNCCS1052478). The project described was supported by the UC Davis Clinical and Translational Science Center. Heejung Bang was partly supported by the National Institutes of Health through grant UL1 TR001860.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of University of California, Davis gave approval for this work and all data used were de-identified prior to analysis
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Support: This work was funded by NIH HeartShare (NIH U01HL160274) and the American Heart Association (AHA) (grant 23SFRNPCS1064232, 23SFRNPCS1060482, and 23SFRNCCS1052478). The project described was supported by the UC Davis Clinical and Translational Science Center. Heejung Bang was partly supported by the National Institutes of Health through grant UL1 TR001860.
Disclosures: The authors declare no conflicts of interest. Funding sources were not involved in the collection and interpretation of data, preparation of the manuscript, and decisions for publication. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. This study was reviewed and approved by UC Davis IRB. All data used were de-identified prior to analysis.
Abbreviations
- BNP
- Brain Natriuretic Peptide
- HF
- Heart Failure
- HFimpEF
- Heart Failure with improved ejection fraction
- HFrEF
- Heart Failure with reduced ejection fraction
- IVSd
- Interventricular septum thickness at end-diastole
- LVEF
- Left ventricular ejection fraction
- LVID
- Left ventricular internal dimension
- PASP
- Pulmonary artery systolic pressure
- RASi
- Renin-Angiotensin-System Inhibitor
- TAPSE
- Tricuspid annular plane systolic excursion
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos